Gérard Milano

发表

Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.

G. Poissonnet, P. Marcy, O. Dassonville, 1998, International journal of radiation oncology, biology, physics.

Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.

C. Létoublon, J. Formento, G. Milano, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.

G. Milano, P. Cuq, J. Ciccolini, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tamoxifen metabolism: pharmacokinetic and in vitro study.

M. Namer, J. Formento, G. Milano, 1989, British Journal of Cancer.

Doxorubicin weekly low dose administration: in vitro cytotoxicity generated by the typical pharmacokinetic profile.

M. Namer, G. Milano, J. Fischel, 1992, European journal of cancer.

Epidermal growth factor receptor expression and suramin cytotoxicity in vitro.

G. Milano, J. Fischel, P. Formento, 1990, European journal of cancer.

Pharmacological background of EGFR targeting.

N. Magné, G. Milano, M. Etienne-Grimaldi, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors

G Milano, G. Milano, J. Fischel, 2005, British Journal of Cancer.

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)

G Milano, N. Magné, P. Laurent-Puig, 2002, British Journal of Cancer.

Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration.

G Milano, G. Milano, J. Fischel, 1992, European journal of cancer.

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines

G Milano, A. Dubreuil, G. Milano, 2001, British Journal of Cancer.

Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.

G. Milano, J. Fischel, P. Formento, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

X. Pivot, G. Milano, P. Canal, 1998, European journal of cancer.

Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.

O. Dassonville, F. Demard, G. Milano, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.

G. Milano, M. Chazal, A. Bourgeon, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data.

G. Milano, J. Fischel, P. Formento, 1997, European journal of cancer.